secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2026-10-15T20:05:33+00:00
Accession:  0001493152-26-047227
Event type: debt
Sentiment:  negative
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Evofem Biosciences sets Dec. 1, 2026 note maturity in fifth amendment with Adjuvant
--------------------------------------------------------------------------------

- Fifth Amendment to the Oct. 14, 2020 Securities Purchase Agreement with Adjuvant Global Health Technology Fund signed Oct. 9, 2026
- Notes plus accrued interest now due in full on earliest of Dec. 1, 2026, a Change of Control elected by Adjuvant, or acceleration under Section 8
- Notes may not be prepaid before Dec. 1, 2026 without Adjuvant's prior written consent
- Section 7.1(f) affirmative covenant deleted in its entirety and replaced with '[Reserved]'
- Adjuvant represented it holds a majority of outstanding note balances, constituting the Requisite Purchasers under Section 10.8

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315226047227/0001493152-26-047227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315226047227/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-047227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer